2 completed, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Type 2 Diabetes Mellitus (T2D): new trials by email Literature Review of Type 2 Diabetes Mellitus (T2D) trials Research Report on Type 2 Diabetes Mellitus (T2D)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D) ESG with OverStitch - Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30) | Not applicable | Not yet recruiting | Boston Scientific Corporation | 50 | 2027-04-01 | 2026-11-06 |
| Culturally Tailored Program for Food-Insecure Adults: SPICE-D Food Bundle Intervention - Type 2 Diabetes Mellitus (T2D) | Not applicable | Recruiting | Wake Forest University Health Sciences | 25 | 2026-04-01 | 2026-10-30 |
| A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants LY3549492, Placebo - Healthy, Type 2 Diabetes Mellitus (T2D) | Phase 1 | Completed | Eli Lilly and Company | 92 | 2025-05-07 | 2026-03-20 |
| Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France Saxagliptin - Type 2 Diabetes Mellitus (T2D) | Completed | AstraZeneca | 1000 | 2012-05-01 | 2016-06-07 |
Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Obesity (1)
Nutritional and Metabolic Diseases (4) · Diabetes Mellitus (3) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Body Weight (1) · Nutrition Disorders (1) · Overnutrition (1) · Overweight (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
saxagliptin (1)
AstraZeneca (1) · Boston Scientific Corporation (1) · Eli Lilly and Company (1) · Wake Forest University Health Sciences (1)
Japan (1) · United States (1)
Ildiko Lingvay, MD (1) · Megan B Irby, PhD (1) · Shailendra Singh, MD (1)